Ozempic vs. Mounjaro vs. Zepbound: A Physician's Comparison (2026)

Ozempic

Ozempic — the diabetes workhorse with the long track record

Ozempic is semaglutide, dosed up to 2 mg weekly, FDA-approved for type 2 diabetes and for cardiovascular risk reduction in adults with diabetes and established cardiovascular disease. It is the GLP-1 with the most years in clinical practice and the deepest cardiovascular safety dataset (SUSTAIN-6, SELECT).

Real-world weight loss on the 2 mg dose typically runs 6–10% of body weight — meaningful, but smaller than what Wegovy or Zepbound deliver because Ozempic's labeled maximum is lower. Most commercial plans cover Ozempic when the diagnosis is type 2 diabetes; coverage for off-label weight loss is rare and usually triggers a switch to Wegovy.

Clinical fit: adults with type 2 diabetes who need glycemic improvement and modest-to-moderate weight loss, patients who have prior cardiovascular disease and would benefit from the SELECT-style risk reduction, and patients prioritizing the longest real-world experience.

Mounjaro

Mounjaro — the most potent diabetes incretin

Mounjaro is tirzepatide — the first dual GIP / GLP-1 receptor agonist — dosed up to 15 mg weekly and FDA-approved for type 2 diabetes only. The dual mechanism produces larger HbA1c reductions and greater weight loss than GLP-1 monotherapy at comparable doses (SURPASS-2).

It is the same molecule as Zepbound at the same dose range; the brands differ only in FDA indication and packaging. Commercial insurance covers Mounjaro broadly for diabetes; coverage for off-label weight loss is rare, and the physician-correct prescription for obesity is Zepbound.

Clinical fit: adults with type 2 diabetes inadequately controlled on first-line therapy, patients who would benefit from substantial weight loss alongside glycemic improvement, and patients who have not tolerated or fully responded to GLP-1 monotherapy. Long-term cardiovascular outcomes data is pending (SURPASS-CVOT).

Zepbound

Zepbound — the highest-efficacy weight-loss medication on the market

Zepbound is tirzepatide approved for chronic weight management in adults with obesity (or overweight with comorbidity) and, after a 2024 label expansion, for moderate-to-severe obstructive sleep apnea in adults with obesity (SURMOUNT-OSA). At the 15 mg dose, mean weight loss in SURMOUNT-1 was ~20.9% at 72 weeks — the largest in any FDA-approved weight medication.

SURMOUNT-5, the first head-to-head trial against Wegovy (semaglutide 2.4 mg), confirmed tirzepatide produces significantly greater weight loss over 72 weeks. Eli Lilly's LillyDirect Self Pay program offers single-dose vials at meaningfully lower cash prices than pens.

Clinical fit: adults with obesity targeting the largest possible weight loss, patients with co-existing OSA, and patients without obesity-drug insurance benefits who can use LillyDirect Self Pay. Long-term cardiovascular outcomes specifically in obesity-without-diabetes are not yet published for tirzepatide.

Decision Framework

Which One Is Right for You?

There is no single best GLP-1 — there is the best GLP-1 for a specific patient's biology, comorbidities, insurance, and life. A board-certified physician weighs these factors before recommending an agent:

• ·Diagnosis: type 2 diabetes (Ozempic or Mounjaro) vs. chronic weight management (Wegovy or Zepbound) vs. obstructive sleep apnea in obesity (Zepbound).
• ·Cardiovascular history: established cardiovascular disease + overweight or obesity points toward semaglutide (Wegovy), which carries the only FDA-recognized cardiovascular-event-reduction indication for this population (SELECT).
• ·Magnitude of weight loss needed: the larger the target, the more tirzepatide outperforms semaglutide in trials (SURMOUNT-5).
• ·Insurance: many plans cover Ozempic and Mounjaro for diabetes broadly; obesity coverage for Wegovy and Zepbound varies by plan and requires prior authorization.
• ·Cash-pay reality: NovoCare Pharmacy ($199 intro → $349–$499) for Ozempic and Wegovy; LillyDirect Self Pay vials ($349–$499+) for Zepbound and Mounjaro.
• ·Tolerability and comorbidities: history of pancreatitis, gallbladder disease, severe gastroparesis, MTC or MEN2, eating disorder, pregnancy plans — these change the calculus.
• ·Maintenance plan: any of these requires a long-term strategy with body-composition monitoring and lean-mass preservation. Choosing the molecule is step one of a multi-year program, not the whole program.

What to Avoid

A note on compounded semaglutide and tirzepatide

Compounded semaglutide and tirzepatide marketed by online clinics and med-spas are not FDA-approved. The FDA has documented dosing errors, adverse events, and salt-form substitutions (semaglutide sodium, semaglutide acetate) that are not the same active ingredient as the brand-name medications. With both molecules off the FDA shortage list, the legal basis for routine compounding has narrowed sharply.

If brand medication is unaffordable, the better-medicine path is manufacturer self-pay programs, insurance appeals, or a physician-supervised change in strategy — not a compounded vial of unknown provenance.